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eBACKGROUND & AIMS: It is unclear whether mortal-
ity from upper gastrointestinal hemorrhage is changing:
any differences observed might result from changes in age
or comorbidity of patient populations. We estimated
trends in 28-day mortality in England following hospital
admission for gastrointestinal hemorrhage. METHODS:
We used a case-control study design to analyze data from all
adults administered to a National Health Service hospital, for
upper gastrointestinal hemorrhage, from 1999 to 2007 (n 
516,153). Cases were deaths within 28 days of admission (n 
74,992), and controls were survivors to 28 days. The 28-day
mortality was derived from the linked national death register. A
logistic regression model was used to adjust trends in non-
variceal and variceal hemorrhage mortality for age, sex, and
comorbidities and to investigate potential interactions. RE-
ULTS: During the study period, the unadjusted, overall,
8-day mortality following nonvariceal hemorrhage was
educed from 14.7% to 13.1% (unadjusted odds ratio, 0.87;
5% confidence interval: 0.84–0.90). The mortality follow-
ng variceal hemorrhage was reduced from 24.6% to 20.9%
unadjusted odds ratio, 0.8; 95% confidence interval: 0.69–
.95). Adjustments for age and comorbidity partly ac-
ounted for the observed trends in mortality. Different
ortality trends were identified for different age groups
ollowing nonvariceal hemorrhage. CONCLUSIONS:
he 28-day mortality in England following both non-
ariceal and variceal upper gastrointestinal hemor-
hage decreased from 1999 to 2007, and the reduction
ad been partly obscured by changes in patient age
nd comorbidities. Our findings indicate that the
verall management of bleeding has improved within
he first 4 weeks of admission.
eywords: Hospital Episode Statistics; Time Trends; Charl-
on Index; Bleeding.
iew this article’s video abstract at www.gastrojournal.
rg.
Gastrointestinal hemorrhage is the commonest causeof acute hospital admission to gastroenterology and
therefore has a large impact on the acute medical admis-
sion workload. Changes in management have been shown
in randomized controlled trials to improve outcome from
gastrointestinal hemorrhage, but the largest observationalstudies of mortality trends following upper gastrointesti-
nal hemorrhage report no improvement in overall mor-
tality over the last 2 decades.1–3 This failure to demon-
strate an improvement suggests either that clinical
guidelines4,5 derived from the results of randomized con-
trolled trials are not generalizable to the clinical popula-
tion, that they are not being implemented appropriately,
or that the patients have changed at the same time as the
treatments. This latter explanation, with increasing age
and comorbidity confounding the effects of therapy, has
been proposed as the likely explanation.6,7 However, this
as not been proven because to reliably measure the effect
f changes in age and comorbidity on mortality necessi-
ates larger studies than have been published. Therefore,
e aimed to investigate current trends in mortality fol-
owing admission from upper gastrointestinal hemor-
hage in England and investigate whether these can be
xplained by population changes in age and comorbidity.
Patients and Methods
Database
The Hospital Episodes Statistics database (HES)
contains information on all admissions to an NHS hos-
pital in England, with over 12 million new records added
each year. It is managed by the NHS information center
and is available for research with ethical approval. All
NHS hospitals within England are required to contribute
to the database. There are currently 168 acute trusts in
England; however, each of these trusts can manage more
than 1 hospital, and over time trusts can merge and split.
Over the course of our study, approximately 150–200
providers were contributing to the database. The available
data consist of a number of records for each admission,
which are called episodes. Each episode represents the time
period of the admission that a patient was under the
clinical care of a particular consultant team during their
Abbreviations used in this paper: HES, Hospital Episodes Statistics;
NHS, National Health Service; ICD, International Classiﬁcation of Dis-
eases; ONS, Ofﬁce of National Statistics; BSG, British Society of Gas-
troenterology.
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July 2011 UPPER GASTROINTESTINAL HEMORRHAGE MORTALITY 63inpatient stay. A unique patient identifier allows all re-
cords for each patient to be identified and linked together.
Each episode’s time span is defined with a start and finish
date as well as being assigned an admission and discharge
date for the whole period of the inpatient stay. Each
episode will have up to 14 diagnoses coded using Inter-
national Classification of Diseases 10th revision (ICD-10);
and up to 12 procedures coded using the United Kingdom
Tabular List of the Classification of Surgical Operations
and Procedures (OPCS) (version OPCS4). This database
has been linked to the Office of National Statistics (ONS)
death register since 1998.
Study Population
Inclusion criteria. All admissions older than 15
years (chosen to be consistent with the lower age limit of
previous British Society of Gastroenterology (BSG) audits
of mortality in gastrointestinal hemorrhage8,9), which had
n ICD-10 code for upper gastrointestinal hemorrhage,
ith a date of hemorrhage between January 1, 1999, and
ecember 31, 2007, were extracted. Data were available
or 2008 to allow complete follow-up of mortality for
dmissions occurring in December 2007. Upper gastroin-
estinal hemorrhage was defined as an ICD-10 code that
pecifically implied either variceal gastrointestinal hemor-
hage: esophageal varices with hemorrhage (I85.0) or non-
ariceal hemorrhage: Mallory–Weiss syndrome (K22.6),
sophageal hemorrhage (K22.8) acute, or chronic gastric
lcer with hemorrhage including perforation with hem-
rrhage (K25.0, K25.2, K25.4, K25.6), acute or chronic
uodenal ulcer with hemorrhage including perforation
ith hemorrhage (K26.0, K26.2, K26.4, K26.6), acute or
hronic peptic ulcer with hemorrhage including perfora-
ion with hemorrhage (K27.0, K27.2, K27.4, K27.6), acute
r chronic gastrojejunal ulcer with hemorrhage including
erforation with hemorrhage (K28.0, K28.2, K28.4, K28.6),
ematemesis (K92.0), melena (K92.1), or unspecified gastro-
ntestinal hemorrhage (K92.2). This ICD-10 code list has
reviously been used in hospital data.10 Subsequent readmis-
sions with upper gastrointestinal hemorrhage were included
in the study and recorded as a readmission. We performed 2
sensitivity analyses to assess the affect of inaccuracies in
coding. First, to assess the effect of under-reporting, we
expanded the definition for variceal hemorrhage to include
all admissions coded for esophageal hemorrhage (K22.8) and
then reassessed the trends in mortality. Second, to assess
whether there was over-reporting of cases that might not be
a genuine upper gastrointestinal hemorrhage, we analyzed
separately those who had and those who did not have an
intervention of upper gastrointestinal endoscopy recorded
(as defined by an OPCS4 code for an endoscopic procedure
of the upper gastrointestinal tract).
Exclusion criteria. The study population was geo-
graphically limited to patients who were residents within
England at the time of hospital admission. Admissions
were excluded if they were coded with unspecified gastro-
intestinal hemorrhage (K92.2) and had a lower gastroin-
testinal endoscopy/diagnosis code but no upper gastroin-testinal endoscopy code. Admissions were also excluded
with the following: day case admission codes with no
overnight stay (a majority of these admissions were for an
outpatient endoscopy and would not have represented an
acute presentation of hemorrhage but either a complica-
tion of endoscopy or a follow-up endoscopy to a previous
bleed), invalid date codes as flagged by HES, date codes
that were out of chronological order, invalid date of birth
codes, invalid sex codes, or duplicate records for 1 episode.
Outcome
Short-term mortality was defined as a date of
death within 28 days of the start of the recorded episode
of upper gastrointestinal hemorrhage. This included
deaths that occurred after discharge from hospital but
within the 28 days. The date and fact of death were
obtained from the ONS death register using a probability
matching algorithm based on NHS number, date of birth,
postcode, and sex.11
Exposures
The exposure of interest was defined as the year of
upper gastrointestinal hemorrhage. Charlson index,12 sex,
nd age were assessed as potential confounders. The
harlson index was calculated for each upper gastrointes-
inal hemorrhage admission based on the diagnoses
oded for all admissions up to and including the first
pper gastrointestinal hemorrhage admission for each
atient. The Charlson index is a validated comorbidity
core that has been weighted to predict 1-year mortality.
or analysis and reporting, it is combined into 3 groups:
o comorbidity (0), a single comorbidity (1), and multiple
r serious comorbidity (2). For analysis of variceal hem-
rrhage, the comorbidity of liver disease was excluded
rom the calculation of Charlson index because most
ariceal patients will have liver disease. The Charlson
ndex has been adapted and validated for ICD-10 coding
n administrative data13,14 and has previously been used in
ES.15 As a sensitivity analysis, we also assessed the use of
n alternative measure of comorbidity called the Elixhauser
ndex16 that was derived to predict mortality during the
inpatient stay. Although it has the potential to be a more
appropriate measure for our study than the Charlson
index, it has not been previously validated within HES, so
it was not used for our primary analysis. The recorded age
was grouped into age bands of 15–29 years, 30–59 years,
60–79 years, and older than 80 years. A further analysis
assessed whether using a higher minimum age limit of 18
years altered the results. We calculated the length of
inpatient stay as the number of days between admission
and discharge dates. We defined admissions as either
having a higher probability of being an acute bleed on
admission (if an upper gastrointestinal hemorrhage was
coded on the first episode in a nonelective admission) or
as lower probability of being an acute bleed on admission
with a higher probability of being an inpatient bleed (if
the coding occurred after the first episode within a non-
elective admission, or during an elective [nonemergency]
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64 CROOKS ET AL GASTROENTEROLOGY Vol. 141, No. 1admission). Hereafter, these are referred to, respectively, as
acute admissions and inpatient bleeds. To assess trends in
diagnoses that were associated with a gastrointestinal
hemorrhage code, we extracted additional diagnoses for
gastritis/duodenitis, Mallory–Weiss syndrome, any peptic
ulcer, gastric ulcer, duodenal ulcer, and malignancy.
Statistical Analysis
We analyzed variceal and nonvariceal hemorrhage
admissions separately. After the exclusions described
above, 28-day case fatalities were calculated by age group,
sex, year, grouped Charlson index, and acute or inpatient
hemorrhage. A case-control study analysis was carried out
with cases defined as patients who had died by 28 days
and controls as patients who were alive at 28 days. The
primary exposure of interest was defined as year of upper
gastrointestinal hemorrhage. A logistic regression model
was constructed to adjust for the change in mortality over
the study period by sex, age group, and Charlson index.
Variables that changed the odds of mortality were judged
to be confounders. We assessed whether there was a trend
in mortality over time and whether this could be modelled
as a linear trend using likelihood ratio tests. We also
performed a secondary analysis comparing trends in mor-
tality that occurred before discharge and trends in mor-
tality that occurred after discharge. The calculation of
postdischarge mortality excluded patients who had died
as inpatients. In addition, to determine whether the
changes in mortality varied for different ages, sex, and
comorbidities, the model was also tested for interactions
between each of the variables and year of bleed with
likelihood ratio testing. If there was evidence against the
null hypothesis of no interaction, stratified results were
presented. The use of the a priori age groups was assessed
against alternative groupings of 5-year age bands or age as
a linear variable. All analysis was performed using Stata
version 10 (StataCorp LP, College Station, TX).
Results
Study Population and Exclusions
There were 516,153 upper gastrointestinal hemor-
rhage admissions identified after exclusions (shown in
Figure 1) of which 501,471 (97%) were nonvariceal bleeds,
and 14,682 (3%) were variceal bleeds.
Mortality Ascertainment
Seventy-four thousand nine hundred ninety-two
deaths occurred within 28 days of the date of upper
gastrointestinal hemorrhage, giving an overall case fa-
tality rate of 14.5% (95% confidence interval [95% CI]:
14.4%–14.6%). Of these, 10,977 deaths (15%) occurred
after discharge from hospital but within 28 days of
hemorrhage. Only 312 (3%) of postdischarge deaths
were coded as a subsequent hospital admission within
the HES dataset.Univariable Analysis
The population characteristics for nonvariceal and
variceal hemorrhage are shown in Table 1. The median
age for nonvariceal bleeds was 71 years (interquartile
range, 50–81 years) and, for variceal bleeds, was 55 years
(interquartile range, 45–66 years). Forty-six percent of
those presenting with nonvariceal hemorrhage had no
comorbidity recorded, compared with 67% of those pre-
senting with variceal hemorrhage after the exclusion of
liver disease from the calculation of comorbidity. The
population age structure and comorbidity varied over the
study period (Figure 2) with a peak in the proportion of
nonvariceal admissions over 80 years old in 2002. This
matched the peak in case fatality in the same year (Table
1). There was a reduction over time in the proportion of
those presenting with variceal hemorrhage who were less
than 60 years old (Figure 2). The comorbidity for both
groups increased over the study period. Median length of
stay for nonvariceal hemorrhage was 4 days (interquartile
range, 1–8 days) and for variceal hemorrhage was 7 days
(interquartile range, 4–12 days). The length of stay re-
duced over the study period for nonvariceal hemorrhage
from 4 (interquartile range, 2–8 days) to 3 (interquartile
range, 1–6 days) (P  .001 nonparametric test for trend),
but there was no reduction for variceal hemorrhage.
Nonvariceal and Variceal Hemorrhage
The overall 28-day case fatality following a non-
variceal hemorrhage admission was 14% and, following a
variceal hemorrhage admission, was 23% (Table 1). From
Figure 1. Flowchart of exclusions from study population.1999 to 2007, the unadjusted 28-day mortality following
ota
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July 2011 UPPER GASTROINTESTINAL HEMORRHAGE MORTALITY 65nonvariceal hemorrhage reduced from 14.7% to 13.1%
(unadjusted odds ratio [OR], 0.87; 95% CI: 0.84–0.90).
The unadjusted mortality following variceal hemorrhage
reduced from 24.6% to 20.9% (unadjusted OR, 0.81; (95%
CI: 0.69–0.95).
Acute Hemorrhage on Admission Compared
With Inpatient Hemorrhage
Twenty-eight-day mortality for an acute admission
with hemorrhage reduced over the study period for non-
variceal hemorrhage from 11.3% to 9.3% (unadjusted OR,
0.81; 95% CI: 0.77–0.85) and, for variceal hemorrhage,
from 21.3% to 17.3% (unadjusted OR, 0.77; 95% CI: 0.62–
0.95). Twenty-eight-day mortality for cases with an inpa-
tient hemorrhage also reduced over the study period, for
nonvariceal hemorrhage from 20.0% to 18.4% (unadjusted
OR, 0.91; 95% CI: 0.86–0.95) and, for variceal hemor-
rhage, from 32% to 29% (unadjusted OR, 0.88; 95% CI:
0.67–1.14).
Multivariate Analysis
The odds of mortality for each year were altered
when adjusted separately for each of the potential con-
founders of age, sex, and Charlson index. The slight peak
in mortality in 2002 was removed when adjusting for the
Table 1. Population Characteristics
Nonvariceal b
Number of
admissions
(n)
Per
adm
Year
1999 51,843
2000 53,206
2001 53,268
2002 53,735
2003 55,656
2004 57,450
2005 59,362
2006 58,737
2007 58,214
Total 501,471 1
Sex
Male 276,304
Female 225,167
Age, y
30 39,973
30 to 59 135,507
60 to 79 174,181
80 151,810
Charlson index
No comorbidity 229,941
Single comorbidity 150,004
Multiple or serious comorbidity 121,526
Acute hemorrhage on admission or inpatient
Acute hemorrhage on admission 295,887
Inpatient bleed 205,584
NOTE. Linked HES/ONS mortality records are currently provided on a p
records may have been incorrectly rejected. The algorithm that links HE
affects approximately 1000 mortality records or about 0.02% of the tincrease in age in 2002. The use of alternative groupingsfor age did not alter the estimates. An alternative mini-
mum age limit of 18 years did not alter the findings of the
analysis for mortality. Adjusting for increases in comor-
bidity had the largest effect on the reduction in mortality.
The multivariate model adjusting for all these variables is
shown in Table 2. Age and comorbidity were stronger
confounders for nonvariceal than variceal hemorrhage.
There was evidence of a linear trend in mortality over
time, for both nonvariceal hemorrhage and variceal hem-
orrhage (P  .001), and there was minimal evidence to
suggest that a linear model was inappropriate for the data
(test for departure from a linear trend; nonvariceal hem-
orrhage, P  .061; variceal hemorrhage, P  .94). The
adjusted average annual reduction in odds of mortality
for nonvariceal hemorrhage was 2.5% (average annual OR,
0.97; 95% CI: 0.97–0.98) and, for variceal hemorrhage, was
3.5% (average annual OR, 0.96; 95% CI: 0.95–0.98). Assess-
ing age, sex, and comorbidity adjusted trends following
the diagnoses of gastritis/duodenitis, Mallory–Weiss syn-
drome, any peptic ulcer, gastric ulcer, duodenal ulcer, or
malignancy associated with nonvariceal hemorrhage found
that there were similar reductions in mortality following all
these diagnoses (see Table 3). A sensitivity analysis was con-
ducted including esophageal hemorrhage codes (K22.8) as a
d admissions Variceal bleed admissions
tage
ll
ions
28-Day
case
fatality (%)
Number of
admissions
(n)
Percentage
of all
admissions
28-Day
case
fatality (%)
.3 14.7 1559 10.6 24.6
.6 14.8 1592 10.8 25.1
.6 14.9 1496 10.2 25.0
.7 14.9 1581 10.8 24.2
.1 14.7 1619 11.0 23.6
.5 14.1 1768 12.0 22.3
.8 13.9 1612 11.0 21.7
.7 13.7 1736 11.8 20.7
.6 13.1 1719 11.7 20.9
.0 14.3 14,682 100.0 23.1
.1 13.3 9565 65.1 23.0
.9 15.5 5117 34.9 23.2
.0 0.5 375 2.6 10.7
.0 5.5 8749 59.6 21.2
.7 15.1 4688 31.9 25.9
.3 24.8 870 5.9 31.3
.9 6.8 9825 66.9 21.6
.9 13.6 3832 26.1 25.2
.2 29.2 1025 7.0 29.5
.0 10.5 10,176 69.3 20.1
.0 19.7 4506 30.7 29.8
sional basis. An issue has arisen whereby a small number of mortality
o ONS mortality is currently being amended to rectify this issue, which
l.lee
cen
of a
iss
10
10
10
10
11
11
11
11
11
00
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8
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66 CROOKS ET AL GASTROENTEROLOGY Vol. 141, No. 1nual reduction in odds of mortality of 3.6% (average annual
OR, 0.96; 95% CI: 0.95–0.98). The second sensitivity analysis
found a similar reduction in nonvariceal hemorrhage admis-
sions who had an endoscopy recorded (average annual OR,
0.97; 95% CI: 0.96–0.97) to those who did not have an
endoscopy recorded (average annual OR, 0.96; 95% CI: 0.96–
0.97). This was also the case for variceal hemorrhage, al-
though because only a few cases did not have an endoscopy,
there was greater uncertainty (with endoscopy: average an-
nual OR, 0.98; 95% CI: 0.96–0.99; without endoscopy: aver-
age annual OR, 0.95, 95% CI: 0.92–0.98). The third sensitiv-
ity analysis used the Elixhauser index to adjust for
comorbidity, and this showed a slightly increased average
annual reduction compared with using the Charlson index
to adjust for comorbidity (nonvariceal hemorrhage OR, 0.96;
95% CI: 0.96–0.97). However, the overall model with the
Elixhauser index did not have as good a fit to the data as
when the Charlson index was used to adjust for comorbidity.
Reanalyzing the age, sex, and comorbidity adjusted
Figure 2. Trends in age and comorbidity measured by grouped Charls
emorrhage patients in each age band. (B) Percentage of nonvariceal h
emorrhage patients in each age band. (D) Percentage of variceal hemotrends for mortality only occurring before discharge dem- tonstrated the same reduction in inpatient mortality as in
the main analysis (nonvariceal average annual adjusted
mortality OR, 0.97; 95% CI: 0.97–0.98). However, the
mortality after discharge increased slightly (nonvariceal
average annual adjusted mortality OR, 1.02; 95% CI: 1.02–
1.03). Further analyses for interactions demonstrated dif-
ferent time trends for different ages and different levels of
comorbidity for nonvariceal hemorrhage (likelihood ratio
tests for interactions of both age and comorbidity with
year, P  .001) but not for variceal hemorrhage (year and
age, P  .29; year and comorbidity, P  .67). Conse-
uently, the age-specific stratum average annual changes
n odds of mortality for nonvariceal hemorrhage are pre-
ented in Table 4. The annual improvement in odds of
ortality was minimal for those presenting 80 years
nd older compared with all the other age groups.
urther stratifying the model by age and comorbidity
Table 5) demonstrated that, within each age-specific
tratum, the improvement in mortality did not differ by
index (percentage of population shown). (A) Percentage of nonvariceal
orrhage patients in each comorbidity group. (C) Percentage of variceal
age patients in each comorbidity group.on
emhe level of comorbidity. Therefore, the final model of a
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July 2011 UPPER GASTROINTESTINAL HEMORRHAGE MORTALITY 67linear trend in 28-day mortality for nonvariceal hemor-
rhage is the model shown in Table 4, with confounding
by comorbidity adjusted for by logistic regression and
effect modification demonstrated by stratifying the re-
sults by age. The final model of a linear trend in 28-day
mortality for variceal hemorrhage demonstrated only
confounding by both comorbidity and age with no
effect modification.
Table 2. Logistic Regression Model Predicting 28-Day Mortali
Nonvariceal hemorrhage
Unadjusted
odds ratio
Adjusted
odds ratioa
ear of presentation
1999 1.00 1.00
2000 1.00 0.98
2001 1.01 0.97
2002 1.01 0.95
2003 0.99 0.94
2004 0.95 0.90
2005 0.93 0.89
2006 0.92 0.85
2007 0.87 0.80
ge, y
30 1.00 1.00
30–59 10.09 7.22
60–79 30.04 16.80
80 55.62 34.14
ex
Male 1.00 1.00
Female 1.20 1.01
harlson index
No comorbidity 1.00 1.00
Single comorbidity 2.16 1.70
Multiple or serious comorbidity 5.64 4.37
OTE. Linked HES/ONS mortality records are currently provided on a p
ecords may have been incorrectly rejected. The algorithm that links HE
ffects approximately 1000 mortality records or about 0.02% of the t
aAdjusted for all variables in Table.
Table 3. Trends in 28-Day Mortality for Diagnoses
Associated With an Upper Gastrointestinal
Hemorrhage
Diagnosis associated with upper
gastrointestinal hemorrhage
Adjusted
odds ratioa
95% confidence
intervals
Change in mortality for an increment of 1 yearb
No specific diagnosis 0.97 0.97–0.98
Gastritis/duodenitis 0.96 0.94–0.98
Mallory–Weiss syndrome 0.96 0.95–0.97
Any peptic ulcer 0.96 0.93–0.99
Gastric ulcer 0.94 0.93–0.95
Duodenal ulcer 0.96 0.95–0.97
Malignancy 0.95 0.95–0.96
NOTE. Linked HES/ONS mortality records are currently provided on a
provisional basis. An issue has arisen whereby a small number of
mortality records may have been incorrectly rejected. The algorithm
that links HES to ONS mortality is currently being amended to rectify
this issue, which affects approximately 1000 mortality records or
about 0.02% of the total.
aAdjusted for age, sex, and comorbidity by Charlson index.
bYear as a continuous variable.Discussion
The failure of previous studies to demonstrate
improvements in mortality after upper gastrointestinal
hemorrhage at the population level calls into question the
value of therapeutic changes that are of proven benefit to
individuals. In an increasingly challenging economic en-
vironment, clinicians will need to be able to demonstrate
that increased therapeutic expenditure really does bring
benefits. That 28-day mortality for equivalent patients,
following hospital admission for both nonvariceal and
variceal upper gastrointestinal hemorrhage, has reduced
Variceal hemorrhage
5% Confidence
interval
Unadjusted
odds ratio
Adjusted
odds ratioa
95% Confidence
interval
1.00 1.00
0.94–1.01 1.02 1.02 0.87–1.20
0.93–1.00 1.02 1.02 0.86–1.20
0.92–0.99 0.98 0.98 0.83–1.15
0.90–0.97 0.94 0.95 0.80–1.11
0.86–0.93 0.88 0.88 0.75–1.03
0.86–0.92 0.85 0.83 0.70–0.98
0.82–0.88 0.80 0.79 0.67–0.94
0.77–0.83 0.81 0.80 0.67–0.94
1.00 1.00
6.37–8.19 1.93 1.92 1.44–2.55
14.84–19.02 2.51 2.37 1.77–3.17
30.15–38.65 3.26 3.05 2.22–4.20
1.00 1.00
0.99–1.03 1.01 0.96 0.88–1.04
1.00 1.00
1.66–1.74 0.99 1.17 1.07–1.27
4.28–4.47 1.31 1.37 1.18–1.58
sional basis. An issue has arisen whereby a small number of mortality
o ONS mortality is currently being amended to rectify this issue, which
l.
Table 4. Age Stratified Logistic Regression Model Predicting
28-Day Mortality for Nonvariceal Hemorrhage
Adjusted
odds ratioa
95% Confidence
interval
Change in mortality for an increment of 1 yb
30 y 0.92 0.88–0.97
30–59 y 0.97 0.96–0.97
60–79 y 0.97 0.96–0.97
80 y 0.99 0.98–0.99
NOTE. Linked HES/ONS mortality records are currently provided on a
provisional basis. An issue has arisen whereby a small number of
mortality records may have been incorrectly rejected. The algorithm
that links HES to ONS mortality is currently being amended to rectify
this issue, which affects approximately 1000 mortality records or
about 0.02% of the total.
aAdjusted for comorbidity by Charlson index and sex.ty
9
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68 CROOKS ET AL GASTROENTEROLOGY Vol. 141, No. 1by 2% and 3%, respectively, year on year in England over
the period 1999 to 2007 is therefore of great importance.
The demonstration that this can be shown through the
analysis of routinely collected data may be of great value
in the assessment of other conditions.
Strengths and Limitations
When, as in this case, a study’s findings differ
from the previous literature, we must ask whether this
is because the current or previous studies were in error
or whether they are in reality observing different things.
The data source chosen for our study provides key
advantages. The study is the largest to date of mortality
after hospital admission for gastrointestinal hemor-
rhage and therefore has power to demonstrate trends
that would be missed in smaller studies. It also has
power to demonstrate variations in trends between sub-
groups of the population such as the smaller reduction
in mortality in those over 80 years old with nonvariceal
hemorrhage. The provision within the dataset of infor-
mation on the previously suggested confounders of age
and comorbidity is also of great benefit and has allowed
us to clearly show and correct for this confounding.
Another key advantage of the current study is the link-
age of clinical data with the ONS death register, ensuring
that almost all deaths are captured in the study population.
Hospital admission data only capture deaths occurring be-
fore discharge, which we found to be 86% of the deaths
occurring within 28 days. Studies without such linkage will
have missed a proportion of these deaths because postdis-
charge deaths will have been difficult to capture. Further-
more, any change in this capture over time may have biased
results. The linkage used in the current study, depending as
it does on probability matching, still leaves potential for
some underestimation of mortality, but the robustness of
the linkage coupled with its uniform methodology through-
out the study period mean that bias because of this is
unlikely to have occurred. The reduction in length of stay
over the course of the study further emphasises the impor-
tance of identifying deaths following discharge to accurately
calculate trends in mortality. The slight increase in postdis-
charge mortality might imply that the observed earlier dis-
charge of patients was inappropriate; however, if manage-
ment in hospital was no longer of benefit to a patient who is
dying, then discharge might well be the most appropriate
decision. The observed trends might therefore indicate a
shift of unavoidable in-hospital mortality into the postdis-
charge period.
Patients who died in the emergency department before
admission for endoscopy were not included in our study
because hospital admissions data contain information
only on admitted patients. However, because acute admis-
sion to the hospital for all upper gastrointestinal hemor-
rhages was standard practice within England, the admissions
data will have captured almost all other relevant bleed pre-
sentations. We excluded patients who had a nonspecific code
for gastrointestinal hemorrhage with a colonoscopy but no
gastroscopy, and it is possible that these could have had anupper gastrointestinal bleed if they had died before a
planned gastroscopy. However, this would be unlikely be-
cause usual practice would be to perform a gastroscopy
before colonoscopy because of the easier access and greater
therapeutic potential of gastroscopy.
There have been concerns about the accuracy of routine
hospital admissions coding, in particular the coding of
specific operations and the ascertainment of death for
generating mortality rates for specific hospitals. However,
a systematic review found a 91% median accuracy in
diagnostic coding prior to our study period, and the most
recent audit of selected samples of UK hospital data
confirmed accuracy approaching 90%.17 Other compari-
sons of procedure coding have reported similar or higher
rates of coding in the HES database compared with spe-
cialist clinical databases,18,19 and, with specific regard to
upper gastrointestinal hemorrhage, the incidence of pep-
tic ulcer hemorrhage in the HES data from 1992 to 1995
has been shown to be comparable with the 1993 regional
BSG audit (32 vs 29 per 100,000 per year, respectively).
Furthermore, by choosing our study period, we have en-
sured no systematic changes in coding because the
ICD-10 coding system has been in continuous use in HES
from 1995 to present. This, of course, does not exclude
variation in rates of coding over the study period affecting
our estimates. For example, if the potential error in cod-
ing was systematically changing over time with increased
coding of patients’ comorbidity rather than patients hav-
ing more comorbidity, then clearly that could bias our
results. However, the different trends in comorbidity for
variceal and nonvariceal bleed admissions and different
trends in mortality in different age and comorbidity strata
suggest that there was no systematic change in comorbid-
ity coding over the time period of our study. Under-
reporting of the comorbidities in the Charlson index may
have resulted in incomplete adjustment for comorbidity.
However, although the alternative Elixhauser index as-
Table 5. Age and Comorbidity Stratified Logistic Regression
Model Predicting 28-Day Mortality
Age, y
Charlson
index
Adjusted
odds ratioa
95% Confidence
interval
Change in mortality for an increment of 1 yb
80
0 0.96 0.95–0.97
1 0.96 0.95–0.97
2 0.95 0.95–0.96
80
0 1.00 0.99–1.01
1 0.99 0.98–0.99
2 0.98 0.97–0.99
NOTE. Linked HES/ONS mortality records are currently provided on a
provisional basis. An issue has arisen whereby a small number of
mortality records may have been incorrectly rejected. The algorithm
that links HES to ONS mortality is currently being amended to rectify
this issue, which affects approximately 1000 mortality records or
about 0.02% of the total.
aAdjusted for sex.
bOdds ratio for year as a continuous variable.
w
n
t
w
a
w
I
t
(
f
s
t
r
t
d
b
s
o
v
a
1
c
C
LI
N
IC
A
L
A
T
July 2011 UPPER GASTROINTESTINAL HEMORRHAGE MORTALITY 69sessed almost twice the number of comorbidities, it did
not alter the adjustment of comorbidity in the model.
Comorbidity adjustment by either index increased the
magnitude of the mortality reduction, and, therefore, any
residual confounding in this regard would only, we be-
lieve, cause an underestimate of the real mortality trend in
our study.
Other Studies
A PubMed search, to October 2010, found the
largest comparable population-based study for non-
variceal hemorrhage mortality trends used a Canadian
hospital discharge database with ICD-10 and ICD-9
codes. However, it identified less than one-third of the
number of bleeds used for this study (n  142,363) and
as not able to identify a reduction in case fatality for
onvariceal hemorrhage between 1993 and 2003.3 The
researchers adjusted for changes in age but not for
changes in comorbidity. They also only identified deaths
that occurred before discharge. The low mortality identi-
fied in this study (3.5%) is similar to other North Ameri-
can20 and Mediterranean1,21 studies but is much lower
han other European studies.2,22,23 However, a study of
Medicare patients in the United States found that the
proportion being managed as outpatients varied between
states from 18.6% to 45.3%.24 These differences in practice
ould lead to differences in inpatient study populations
nd confound comparisons with countries such as England
here outpatient management is not routine.
Although the most recent report from the US National
npatient Sample showed a 23% reduction in upper gas-
rointestinal hemorrhage mortality from 1998 to 2006
n  unreported because only extrapolated estimates
rom the 20% sample are provided),20 this was a global
figure for the reduction seen at the end of the study rather
than year on year, and it did not distinguish variceal and
nonvariceal hemorrhage. Another report from the US Na-
tional Inpatient Sample noted an adjusted reduction in
variceal hemorrhage from 18% to 12%.25 However, in the
tudy period of both these reports, the number of states in
he sampling frame almost doubled from 22 to 40. The
eports therefore compare different populations from each
ime period, and, although a number of weighting proce-
ures are used, the estimates remain susceptible to selection
ias.
One smaller study from Wales (n  24,421) used the
ame ICD-10 definitions as our study and also found an
verall reduction in case fatality but did not report
ariceal and nonvariceal hemorrhage mortality trends sep-
rately or trends in different age and comorbidity strata.10
Other nonvariceal hemorrhage studies from Spain (n 
7,663),1 The Netherlands (n  1720),2 Greece (n 
1304),21 France (n  1165),23 and Italy (n  1126)22 did
not identify reductions in nonvariceal inpatient mortality.
Although these were large studies, they may have been
underpowered to detect a change, and none of them
adjusted the trends in case fatality for changes in comor-
bidity. Furthermore, none of these studies identifieddeaths that occurred after discharge. The remainder of the
studies contained less than 1000 patients and therefore
could not provide accurate estimates of mortality trends.
For variceal hemorrhage, the largest study on mortality
after hospitalization because of varices (n  12,281; com-
pared with 14,682 for this study) did not differentiate
between hemorrhage and nonhemorrhage admissions.26
The next largest study (n  1475) compared variceal
hemorrhage mortality between control groups in random-
ized trials 1960–2000 and showed a similar reduction in
mortality.27 However, these control groups were from
different geographical populations with different study
exclusion criteria. Comparisons were therefore susceptible
to selection bias. Other studies of trends in variceal hem-
orrhage mortality contained less than 1000 patients.
The other finding of note in our study in relation to
variceal hemorrhage is the small proportion of overall
hemorrhages that they represent. In the context of the
increasing burden of liver disease28 and an apparent in-
rease in variceal hemorrhage in the recent BSG audit,8 a
higher proportion might have been expected. Our finding,
however, was similar to that from the 1993 BSG audit
(4%) and to other studies.9,29 It is possible that some of the
variceal hemorrhages in our study may have been incor-
rectly coded to esophageal hemorrhage, but a sensitivity
analysis, assuming the most likely misclassification of all
esophageal hemorrhage codes being miscoded variceal
bleeds, did not alter the adjusted reduction in mortality.
The previous difficulties in detecting a reduction in
mortality might imply that we are reaching the point
where mortality becomes unavoidable because of age and
comorbidity. However, because the mortality in our study
continued to improve right up to the end of the study
period, improvements in management would appear to be
continuing to have an impact on mortality following
gastrointestinal hemorrhage. The reasons for the reduc-
tion in mortality we have observed are likely to be com-
plex. There were similar reductions in mortality whether
or not an endoscopy was recorded and for all associated
diagnoses, implying that endoscopic therapy was not a
major contributor to the reduction in mortality. Instead,
our data perhaps suggest that improvement in standard
nonendoscopic care has led to improved survival, such as
the routine administration of intravenous proton pump
inhibitor infusions, the routine use of risk scoring, the
implementation of standardized clinical guidelines, and
the subsequent local auditing of practice.4,5,30
In conclusion, contrary to previous smaller studies, we
have found an encouraging substantial improvement in
mortality following hospital admission for upper gastro-
intestinal hemorrhage. Our study shows that this is par-
tially obscured by changes in age and comorbidity and
that the improvements are less marked in the elderly
individuals in a manner not explained by comorbidity. We
believe that this improvement reflects the effect of
changes in the care of gastrointestinal hemorrhage over
the last decade, but it also suggests the need to focus our
ongoing attention on the elderly individuals who may not
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70 CROOKS ET AL GASTROENTEROLOGY Vol. 141, No. 1yet have benefited to the maximum possible extent from
these changes. The recent demonstration of under-utili-
zation of endoscopic techniques in the United Kingdom,
coupled with the fact that other interventions such as use
of proton pump inhibitors are more readily available to
the admitting physician worldwide, may suggest areas
that could be further improved.4,5,31–33
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